Similar articles for PMID: 33077524

Year	Number of Results
2016	2
2017	10
2018	15
2019	30
2020	30
2021	12
2022	5
2023	0

1

Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors.

Chin-Yee B, Solh Z, Hsia C. Chin-Yee B, et al. CMAJ. 2020 Oct 19;192(42):E1271. doi: 10.1503/cmaj.76686. CMAJ. 2020. PMID: 33077524 Free PMC article. No abstract available.

2

Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases.

Motta G, Zavattaro M, Romeo F, Lanfranco F, Broglio F. Motta G, et al. J Clin Endocrinol Metab. 2019 Mar 1;104(3):819-822. doi: 10.1210/jc.2018-01702. J Clin Endocrinol Metab. 2019. PMID: 30395251

3

Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases.

Gupta R, Gupta A, Shrikhande M, Tyagi K, Ghosh A, Misra A. Gupta R, et al. Diabetes Res Clin Pract. 2020 Apr;162:108127. doi: 10.1016/j.diabres.2020.108127. Epub 2020 Mar 26. Diabetes Res Clin Pract. 2020. PMID: 32224163

4

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.

Matsubayashi Y, Yoshida A, Suganami H, Oe M, Sato T, Yaguchi Y, Fujihara K, Yamada T, Tanaka S, Kaku K, Sone H. Matsubayashi Y, et al. Diabetes Obes Metab. 2022 Dec;24(12):2469-2473. doi: 10.1111/dom.14836. Epub 2022 Sep 12. Diabetes Obes Metab. 2022. PMID: 35979908 Free PMC article. No abstract available.

5

Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

Neuen BL, Cherney DZ, Jardine MJ, Perkovic V. Neuen BL, et al. CMAJ. 2019 Oct 15;191(41):E1128-E1135. doi: 10.1503/cmaj.190047. CMAJ. 2019. PMID: 31615819 Free PMC article. Review. No abstract available.

6

Sarcopenia, frailty circle and treatment with sodium-glucose cotransporter 2 inhibitors.

Sasaki T. Sasaki T. J Diabetes Investig. 2019 Mar;10(2):193-195. doi: 10.1111/jdi.12966. Epub 2018 Nov 30. J Diabetes Investig. 2019. PMID: 30369086 Free PMC article.

7

Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type 2 diabetes mellitus: a case report.

Vadasz B, Arazi M, Shukha Y, Koren O, Taher R. Vadasz B, et al. J Med Case Rep. 2021 Feb 14;15(1):62. doi: 10.1186/s13256-020-02607-2. J Med Case Rep. 2021. PMID: 33581735 Free PMC article.

8

Diabetic ketoacidosis with sodium-glucose cotransporter type 2 inhibitors: a case series.

McLachlan G, Keith C, Frauman A. McLachlan G, et al. Med J Aust. 2019 Sep;211(5):237-237.e1. doi: 10.5694/mja2.50302. Epub 2019 Aug 16. Med J Aust. 2019. PMID: 31420875 No abstract available.

9

Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis.

Hamblin PS, Wong R, Bach LA. Hamblin PS, et al. Med J Aust. 2021 Feb;214(2):94-94.e1. doi: 10.5694/mja2.50898. Epub 2020 Dec 21. Med J Aust. 2021. PMID: 33349919 No abstract available.

10

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.

Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS. Berg DD, et al. Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31. Circulation. 2019. PMID: 31474116 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed